Adderall XR Sales Rebounding, Shire Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of Shire's attention deficit/hyperactivity disorder agent Adderall XR (extended-release amphetamine) are rebounding after negative publicity that followed Health Canada's suspension of the product
You may also be interested in...
Shire/TKT Merger Deal Focuses On Dynepo Rights In Europe
Shire will promote TKT's Dynepo in Europe with part of its 200-person Fosrenol sales force. European rights to the erythropoietin product were one of the critical components to the $1.6 bil. acquisition. The deal also brings Shire two products in development.
ADHD Market Hurt By Safety Concerns, Lilly Says
Strattera marketer says that label change and withdrawal of Shire's Adderall XR in Canada has slowed the growth of the attention deficit/hyperactivity disorder market. Lilly will focus on consumers with new DTC ad designed to encourage adult patients to seek treatment.
Shire Adderall XR Sales Suspended In Canada; FDA Stands By "Black Box"
Company plans a "Dear Doctor" letter informing U.S. physicians of Health Canada's decision. FDA says it "has not decided to take any further regulatory action at this time"; sudden death warnings were added to Adderall XR's labeling in August.